Wnt / Hedgehog / Notch
Phospho-GSK-3α (Ser21) Blocking Peptide
|
イイネ！(0)
| 
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1027S | 100 μg | 16,000 | |
|
GSK3-alpha抗体製品一覧
| 使用目的 | |
| Phospho-GSK-3α (Ser21) (36E9) Rabbit mAb （#9316）の反応をブロックし、抗体の反応特異性を確認するために使用 |
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using Phospho-GSK-3α (Ser21) (36E9) Rabbit mAb #9316 in the presence of control peptide (left) or Phospho-GSK-3α (Ser21) (36E9) Blocking Peptide (right).
Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).
-
Welsh, G.I. et al. (1996) Trends Cell. Biol. 6, 274-279.
-
Srivastava, A.K. and Pandey, S.K. (1998) Mol. Cell. Biochem. 182, 135-141.
-
Cross, D.A. et al. (1995) Nature 378, 785-789.
-
Nusse, R. (1997) Cell 89, 321-323.
-
Diehl, J.A. et al. (1998) Genes Dev. 12, 3499-3511.
